期刊论文详细信息
Viruses
Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
Wataru Ogura1  Hiroyuki Miyagi1  Takahiro Okuyama1  Kumiko Sekiguchi1  Sachiko Matsuura1  Takashi Watanabe2  Satsuki Matsushima2  Hiroaki Ohnishi2  Kouki Ohtsuka2  Satoko Yamasaki2 
[1] Department of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo 181-8611, Japan;Department of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, Japan;
关键词: coronavirus disease 2019;    severe acute respiratory syndrome coronavirus 2;    mRNA vaccine;    anti-spike antibody;    neutralizing antibody;   
DOI  :  10.3390/v14050956
来源: DOAJ
【 摘 要 】

In Japan, healthcare workers (HCWs) are vaccinated against measles, rubella, chickenpox, mumps, and hepatitis B to prevent nosocomial infection; however, some do not produce sufficient antibodies (“suboptimal responders”). This study compared immune responses to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 mRNA) vaccine among HCWs with normal and suboptimal responses to conventional vaccines. In this prospective cohort study, 50 HCWs received two doses of BNT162b2 mRNA vaccine 3 weeks apart. SARS-CoV-2 anti-spike antibodies were measured 11 times, starting before the first vaccination and ending 5 months after the second vaccination. Antibody titers of four suboptimal and 46 normal responders were compared. SARS-CoV-2 neutralizing antibody activity was measured twice in suboptimal responders, 1 week/1 month and 5 months after the second vaccination. The SARS-CoV-2 anti-spike antibody was detectable in the samples from suboptimal and normal responders at each timepoint after vaccination. Suboptimal responders exhibited SARS-CoV-2 neutralizing antibody activity 1 week/1 month as well as 5 months after the second vaccination; however, activity was slightly reduced at 5 months. Our findings show that suboptimal responders do acquire adequate SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies from vaccination to prevent SARS-CoV-2. SARS-CoV-2 mRNA vaccines should thus be recommended for both normal and suboptimal responders to conventional vaccines.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次